Using GM-CSF to Boost Chemotherapy for Ovarian Cancer
Author Information
Author(s): S. Kehoe, C.J. Poole, A. Stanley, H.M. Earl, G.R.P. Blackledge
Primary Institution: Cancer Research Campaign Trials Unit, Queen Elizabeth Medical Centre, Birmingham, UK
Hypothesis
Can recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support intensify chemotherapy for advanced ovarian cancer?
Conclusion
The study found that while rH GM-CSF can support chemotherapy intensification, it is associated with significant risks and complications.
Supporting Evidence
- Four patients completed the treatment, but one died from a toxic reaction.
- Two patients experienced life-threatening infections.
- Three patients withdrew from the study due to side effects related to rH GM-CSF.
Takeaway
Doctors wanted to see if a special medicine could help make chemotherapy work better for women with advanced ovarian cancer, but it caused some serious problems.
Methodology
Eight patients with advanced ovarian cancer were treated with a combination of cisplatin and cyclophosphamide, supported by rH GM-CSF, to assess the feasibility of a shortened treatment interval.
Potential Biases
Potential bias due to the small number of participants and the nature of the treatment.
Limitations
The small sample size and the high rate of complications limit the generalizability of the findings.
Participant Demographics
Patients aged 39-66 years with histologically confirmed epithelial ovarian carcinoma.
Want to read the original?
Access the complete publication on the publisher's website